NCT06015711 The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement
| NCT ID | NCT06015711 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ajou University School of Medicine |
| Condition | Opioid Use |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2023-08-30 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2023-08-30 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Maxigesic is combined intravenous analgesic of ibuprofen and acetaminphen. The purpose of this study is investigate weather preoperative Maxigesic administration can reduce intraoperative remifentanil requirement.
Eligibility Criteria
Inclusion Criteria: * Adult patients (19-60 years old) with ASA physical status 1, 2, 3 * Scheduled surgery under general anesthesia Exclusion Criteria: * The patient does not conset * Pregnancy * hepatic disorder * Renal disorder * Asthma * Hypersensitivity to the NSAIDs or acetaminophen * Patients receiving chronic pain therapy * Drug dependence * Patients taking psychiatric drugs * Alcoholics * History of gastrointestinal ulcer or bleeding
Contact & Investigator
In Kyong Yi, MD
PRINCIPAL INVESTIGATOR
Ajou University School of Medicine
Frequently Asked Questions
Who can join the NCT06015711 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 60 Years, studying Opioid Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06015711 currently recruiting?
Yes, NCT06015711 is actively recruiting participants. Contact the research team at lyrin01@gmail.com for enrollment information.
Where is the NCT06015711 trial being conducted?
This trial is being conducted at Suwon, South Korea.
Who is sponsoring the NCT06015711 clinical trial?
NCT06015711 is sponsored by Ajou University School of Medicine. The principal investigator is In Kyong Yi, MD at Ajou University School of Medicine. The trial plans to enroll 96 participants.